The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Chugai to Divest Oxarol Injection to LTL in Japan
Chugai Pharmaceutical will transfer the business of the secondary hyperparathyroidism drug Oxarol for Injection (maxacalcitol) to LTL Pharma in Japan, the two companies said on August 28. The transfer of the drug’s marketing authorization will take place on October 1,…
To read the full story
Related Article
- Chugai Completes Transfer of 3 Dermatology Products to Maruho
December 3, 2019
- Chugai to Transfer Japan Rights for 3 Topical Maxacalcitol Products to Maruho
January 31, 2019
BUSINESS
- Pharma Hails End to “Spillover” Rule, Vows to Keep Fighting Off-Year Cuts
December 25, 2025
- Drug Wholesalers Slam “No-Discussion” Decision on FY2027 Off-Year Price Revision
December 25, 2025
- JCR Earns Japan Rights to DMD Drug from Italfarmaco
December 25, 2025
- Fujifilm Completes Major Biologics CDMO Plant in Toyama, Eyes 2027 Start-Up
December 25, 2025
- Alfresa’s Cell Resources Inks Partnership with Korea’s ENCell
December 25, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…